Skip to main content
Erschienen in: Inflammation 2/2012

01.04.2012

Triple Inhibitory Activity of Cliona celata Against TNF-α-Induced Matrix Metalloproteinase-9 Production Via Downregulated NF-κB and AP-1, Enzyme Activity, and Migration Potential

verfasst von: Seok-Jong Suh, Choong-Hwan Kwak, Kwon-Ho Song, Kyung-Min Kwon, Tae-Wook Chung, Seung-Hak Cho, Yeon-Kye Kim, Ho-Dong Yoon, Young-Choon Lee, Dong-Soo Kim, Sung-Jae Park, Min Kyun Na, Jong-Keun Son, Hyeun Wook Chang, Cheorl-Ho Kim

Erschienen in: Inflammation | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Extracellular matrix-degrading protease, matrix metalloproteinase-9 (MMP-9), is known to be involved in vascular smooth muscle cell (SMC)’s aberrant proliferation and movement in atherosclerotic lesions. During screening of the MMP-9-inhibitory compounds from marine animal resources, we have found that the ethyl acetate extract from Cliona celata (ECC) effectively inhibits the SMC-derived MMP-9 enzyme activity and gene expression. In addition, the ECC effectively repressed the migration potential of the tumor necrosis factor-α (TNF-α)-stimulated human aortic smooth muscle cell (HASMC). As assessed by Western blot analysis, the produced MMP-9 protein levels in the TNF-α-induced HASMC were significantly decreased by the concomitant treatment of ECC at the 50- to 300-μg/mL concentration ranges. In addition, in the RT-PCR experiment, the expressed MMP-9 mRNA levels in the TNF-α-induced HASMC were seemingly decreased by ECC treatment at the same concentration ranges (50–300 μg/mL). For the action mechanism(s) of ECC to the phenotype changes in HASMC, we have further evaluated the ECC’s pharmacological activities on the signal molecules which are importantly linked in the MMP-9 expression and cell migration potential of HASMC. We have found that extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation as a target point is suppressed by the ECC treatment in the TNF-α-treated HASMC. Using electrophoretic mobility shift assay, the nuclear extracts purified from ECC-treated HASMCs were shown to decrease the binding potentials on the labeled nuclear factor-kappaB (NF-κB) and activator protein 1 probes. NF-κB p65 and phosphorylated c-Jun contents were also decreased in the purified nuclear extracts from the ECC-treated HASMC, as confirmed by Western blot analysis. Finally, it was shown that the ECC-treated HASMCs were less migrated when compared to the TNF-α-treated cells, as confirmed by HASMC migration assays using the 8-μm pore transwell membranes. From these results, it was proposed that ECC has a potentially applicable anti-atherosclerotic activity.
Literatur
1.
Zurück zum Zitat Keyzers, R.A., and M.T. Davies-Coleman. 2005. Anti-inflammatory metabolites from marine sponges. Chemical Society Reviews 34: 355–365.PubMedCrossRef Keyzers, R.A., and M.T. Davies-Coleman. 2005. Anti-inflammatory metabolites from marine sponges. Chemical Society Reviews 34: 355–365.PubMedCrossRef
2.
Zurück zum Zitat Posadas, I., S. De Rosa, M.C. Terencio, M. Paya, and M.J. Alcaraz. 2003. Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation. British Journal of Pharmacology 138: 1571–1579.PubMedCrossRef Posadas, I., S. De Rosa, M.C. Terencio, M. Paya, and M.J. Alcaraz. 2003. Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation. British Journal of Pharmacology 138: 1571–1579.PubMedCrossRef
3.
Zurück zum Zitat Garcia-Pastor, P., A. Randazzo, L. Gomez-Paloma, M.J. Alcaraz, and M. Paya. 1999. Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. The Journal of Pharmacology and Experimental Therapeutics 289: 166–172.PubMed Garcia-Pastor, P., A. Randazzo, L. Gomez-Paloma, M.J. Alcaraz, and M. Paya. 1999. Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. The Journal of Pharmacology and Experimental Therapeutics 289: 166–172.PubMed
4.
Zurück zum Zitat Ettinger-Epstein, P., D.M. Tapiolas, C.A. Motti, A.D. Wright, C.N. Battershill, and R. de Nys. 2008. Production of manoalide and its analogues by the sponge Luffariella variabilis is hardwired. Marine Biotechnology (New York, N.Y.) 10: 64–74.CrossRef Ettinger-Epstein, P., D.M. Tapiolas, C.A. Motti, A.D. Wright, C.N. Battershill, and R. de Nys. 2008. Production of manoalide and its analogues by the sponge Luffariella variabilis is hardwired. Marine Biotechnology (New York, N.Y.) 10: 64–74.CrossRef
5.
Zurück zum Zitat Lucas, R., A. Casapullo, L. Ciasullo, L. Gomez-Paloma, and M. Paya. 2003. Cycloamphilectenes, a new type of potent marine diterpenes: inhibition of nitric oxide production in murine macrophages. Life Sciences 72: 2543–2552.PubMedCrossRef Lucas, R., A. Casapullo, L. Ciasullo, L. Gomez-Paloma, and M. Paya. 2003. Cycloamphilectenes, a new type of potent marine diterpenes: inhibition of nitric oxide production in murine macrophages. Life Sciences 72: 2543–2552.PubMedCrossRef
6.
Zurück zum Zitat Gunasekera, S.P., R.A. Isbrucker, R.E. Longley, A.E. Wright, S.A. Pomponi, and J.K. Reed. 2004. Plakolide A, a new gamma-lactone from the marine sponge Plakortis sp. Journal of Natural Products 67: 110–111.PubMedCrossRef Gunasekera, S.P., R.A. Isbrucker, R.E. Longley, A.E. Wright, S.A. Pomponi, and J.K. Reed. 2004. Plakolide A, a new gamma-lactone from the marine sponge Plakortis sp. Journal of Natural Products 67: 110–111.PubMedCrossRef
7.
Zurück zum Zitat Newby, A.C., and A.B. Zaltsman. 2000. Molecular mechanisms in intimal hyperplasia. The Journal of Pathology 190: 300–309.PubMedCrossRef Newby, A.C., and A.B. Zaltsman. 2000. Molecular mechanisms in intimal hyperplasia. The Journal of Pathology 190: 300–309.PubMedCrossRef
8.
Zurück zum Zitat Bendeck, M.P., C. Irvin, and M.A. Reidy. 1996. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circulation Research 78: 38–43.PubMed Bendeck, M.P., C. Irvin, and M.A. Reidy. 1996. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circulation Research 78: 38–43.PubMed
9.
Zurück zum Zitat Cho, A., and M.A. Reidy. 2002. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circulation Research 91: 845–851.PubMedCrossRef Cho, A., and M.A. Reidy. 2002. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circulation Research 91: 845–851.PubMedCrossRef
10.
Zurück zum Zitat Senior, R.M., G.L. Griffin, C.J. Fliszar, S.D. Shapiro, G.I. Goldberg, and H.G. Welgus. 1991. Human 92- and 72-kilodalton type IV collagenases are elastases. The Journal of Biological Chemistry 266: 7870–7875.PubMed Senior, R.M., G.L. Griffin, C.J. Fliszar, S.D. Shapiro, G.I. Goldberg, and H.G. Welgus. 1991. Human 92- and 72-kilodalton type IV collagenases are elastases. The Journal of Biological Chemistry 266: 7870–7875.PubMed
11.
Zurück zum Zitat Galis, Z.S., M. Muszynski, G.K. Sukhova, E. Simon-Morrissey, E.N. Unemori, M.W. Lark, E. Amento, and P. Libby. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circulation Research 75: 181–189.PubMed Galis, Z.S., M. Muszynski, G.K. Sukhova, E. Simon-Morrissey, E.N. Unemori, M.W. Lark, E. Amento, and P. Libby. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circulation Research 75: 181–189.PubMed
12.
Zurück zum Zitat Fabunmi, R.P., A.H. Baker, E.J. Murray, R.F. Booth, and A.C. Newby. 1996. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. The Biochemical Journal 315(Pt 1): 335–342.PubMed Fabunmi, R.P., A.H. Baker, E.J. Murray, R.F. Booth, and A.C. Newby. 1996. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. The Biochemical Journal 315(Pt 1): 335–342.PubMed
13.
Zurück zum Zitat Cho, A., J. Graves, and M.A. Reidy. 2000. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 20: 2527–2532.PubMedCrossRef Cho, A., J. Graves, and M.A. Reidy. 2000. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 20: 2527–2532.PubMedCrossRef
14.
Zurück zum Zitat Yao, J., S. Xiong, K. Klos, N. Nguyen, R. Grijalva, P. Li, and D. Yu. 2001. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066–8074.PubMedCrossRef Yao, J., S. Xiong, K. Klos, N. Nguyen, R. Grijalva, P. Li, and D. Yu. 2001. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066–8074.PubMedCrossRef
15.
Zurück zum Zitat Faisal Khan, K.M., D.J. Falcone, and R. Kraemer. 2002. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. The Journal of Biological Chemistry 277: 2353–2359.CrossRef Faisal Khan, K.M., D.J. Falcone, and R. Kraemer. 2002. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. The Journal of Biological Chemistry 277: 2353–2359.CrossRef
16.
Zurück zum Zitat Brew, K., D. Dinakarpandian, and H. Nagase. 2000. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochimica et Biophysica Acta—Gene Structure and Expression 1477: 267–283. Brew, K., D. Dinakarpandian, and H. Nagase. 2000. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochimica et Biophysica Acta—Gene Structure and Expression 1477: 267–283.
17.
Zurück zum Zitat Mandal, M., A. Mandal, S. Das, T. Chakraborti, and C. Sajal. 2003. Clinical implications of matrix metalloproteinases. Molecular and Cellular Biochemistry 252: 305–329.PubMedCrossRef Mandal, M., A. Mandal, S. Das, T. Chakraborti, and C. Sajal. 2003. Clinical implications of matrix metalloproteinases. Molecular and Cellular Biochemistry 252: 305–329.PubMedCrossRef
18.
Zurück zum Zitat Zempo, N., N. Koyama, R.D. Kenagy, H.J. Lea, and A.W. Clowes. 1996. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 28–33.PubMedCrossRef Zempo, N., N. Koyama, R.D. Kenagy, H.J. Lea, and A.W. Clowes. 1996. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 28–33.PubMedCrossRef
19.
Zurück zum Zitat Kenagy, R.D., S. Vergel, E. Mattsson, M. Bendeck, M.A. Reidy, and A.W. Clowes. 1996. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 1373–1382.PubMedCrossRef Kenagy, R.D., S. Vergel, E. Mattsson, M. Bendeck, M.A. Reidy, and A.W. Clowes. 1996. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arteriosclerosis, Thrombosis, and Vascular Biology 16: 1373–1382.PubMedCrossRef
20.
Zurück zum Zitat Fitzgerald, M., I.P. Hayward, A.C. Thomas, G.R. Campbell, and J.H. Campbell. 1999. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis 145: 97–106.PubMedCrossRef Fitzgerald, M., I.P. Hayward, A.C. Thomas, G.R. Campbell, and J.H. Campbell. 1999. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis 145: 97–106.PubMedCrossRef
21.
Zurück zum Zitat Yang, J.H., S.J. Suh, Y. Lu, X. Li, Y.K. Lee, Y.C. Chang, M.K. Na, J.H. Choi, C.H. Kim, J.K. Son, and H.W. Chang. 2011. Anti-inflammatory activity of ethylacetate fraction of Cliona celata. Immunopharmacology and Immunotoxicology 33: 373–379.PubMedCrossRef Yang, J.H., S.J. Suh, Y. Lu, X. Li, Y.K. Lee, Y.C. Chang, M.K. Na, J.H. Choi, C.H. Kim, J.K. Son, and H.W. Chang. 2011. Anti-inflammatory activity of ethylacetate fraction of Cliona celata. Immunopharmacology and Immunotoxicology 33: 373–379.PubMedCrossRef
22.
Zurück zum Zitat Keyzers, R.A., J. Daoust, M.T. Davies-Coleman, R. Van Soest, A. Balgi, E. Donohue, M. Roberge, and R.J. Andersen. 2008. Autophagy-modulating aminosteroids isolated from the sponge Cliona celata. Organic Letters 10: 2959–2962.PubMedCrossRef Keyzers, R.A., J. Daoust, M.T. Davies-Coleman, R. Van Soest, A. Balgi, E. Donohue, M. Roberge, and R.J. Andersen. 2008. Autophagy-modulating aminosteroids isolated from the sponge Cliona celata. Organic Letters 10: 2959–2962.PubMedCrossRef
23.
Zurück zum Zitat Suh, S.J., M.K. Na, J.R. Kim, K.M. Kwon, H.K. Ko, K.H. Song, Y.C. Chang, Y.C. Lee, D.S. Kim, S.J. Park, J.H. Yang, J.K. Son, H.W. Chang, and C.H. Kim. 2011. Ethylacetate fraction from Korean seaside starfish, Asterias amurensis has an inhibitory effect on MMP-9 activity and expression and on migration behaviour of TNF-α induced human aortic smooth muscle cells. Toxicology In Vitro 25: 767–773.PubMedCrossRef Suh, S.J., M.K. Na, J.R. Kim, K.M. Kwon, H.K. Ko, K.H. Song, Y.C. Chang, Y.C. Lee, D.S. Kim, S.J. Park, J.H. Yang, J.K. Son, H.W. Chang, and C.H. Kim. 2011. Ethylacetate fraction from Korean seaside starfish, Asterias amurensis has an inhibitory effect on MMP-9 activity and expression and on migration behaviour of TNF-α induced human aortic smooth muscle cells. Toxicology In Vitro 25: 767–773.PubMedCrossRef
24.
Zurück zum Zitat Cha, B.Y., C.J. Park, D.G. Lee, Y.C. Lee, D.W. Kim, J.D. Kim, W.G. Seo, and C.H. Kim. 2003. Inhibitory effect of methanol extract of Euonymus alatus on matrix metalloproteinase-9. Journal of Ethnopharmacology 85: 163–167.PubMedCrossRef Cha, B.Y., C.J. Park, D.G. Lee, Y.C. Lee, D.W. Kim, J.D. Kim, W.G. Seo, and C.H. Kim. 2003. Inhibitory effect of methanol extract of Euonymus alatus on matrix metalloproteinase-9. Journal of Ethnopharmacology 85: 163–167.PubMedCrossRef
25.
Zurück zum Zitat Chung, T.W., S.K. Moon, Y.C. Chang, J.H. Ko, Y.C. Lee, G. Cho, S.H. Kim, J.G. Kim, and C.H. Kim. 2004. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastasis by dual mechanism. The FASEB Journal 18: 1670–1681.CrossRef Chung, T.W., S.K. Moon, Y.C. Chang, J.H. Ko, Y.C. Lee, G. Cho, S.H. Kim, J.G. Kim, and C.H. Kim. 2004. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastasis by dual mechanism. The FASEB Journal 18: 1670–1681.CrossRef
26.
Zurück zum Zitat Suh, S.J., U.H. Jin, H.J. Choi, H.W. Chang, J.K. Son, S.H. Lee, S.J. Jeon, K.H. Son, Y.C. Chang, Y.C. Lee, and C.H. Kim. 2006. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochemical Pharmacology 72: 1680–1689.PubMedCrossRef Suh, S.J., U.H. Jin, H.J. Choi, H.W. Chang, J.K. Son, S.H. Lee, S.J. Jeon, K.H. Son, Y.C. Chang, Y.C. Lee, and C.H. Kim. 2006. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochemical Pharmacology 72: 1680–1689.PubMedCrossRef
27.
Zurück zum Zitat Galis, Z.S., C. Johnson, D. Godin, R. Magid, J.M. Shipley, R.M. Senior, and E. Ivan. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circulation Research 91: 852–859.PubMedCrossRef Galis, Z.S., C. Johnson, D. Godin, R. Magid, J.M. Shipley, R.M. Senior, and E. Ivan. 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circulation Research 91: 852–859.PubMedCrossRef
28.
Zurück zum Zitat Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801–809.PubMedCrossRef Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801–809.PubMedCrossRef
29.
Zurück zum Zitat Goetze, S., X.P. Xi, Y. Kawano, H. Kawano, E. Fleck, W.A. Hsueh, and R.E. Law. 1999. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33: 183–189.PubMed Goetze, S., X.P. Xi, Y. Kawano, H. Kawano, E. Fleck, W.A. Hsueh, and R.E. Law. 1999. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33: 183–189.PubMed
30.
Zurück zum Zitat Moon, S.K., B.Y. Cha, and C.H. Kim. 2004. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the ras dependent pathway. Journal of Cellular Physiology 198: 417–427.PubMedCrossRef Moon, S.K., B.Y. Cha, and C.H. Kim. 2004. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the ras dependent pathway. Journal of Cellular Physiology 198: 417–427.PubMedCrossRef
31.
Zurück zum Zitat Suh, S.J., K.J. Cho, T.C. Moon, H.W. Chang, Y.G. Park, and C.H. Kim. 2008. 3,4,5-Trihydroxybenzaldehyde from Geum japonicum has dual inhibitory effect on matrix metalloproteinase 9; inhibition of gelatinoytic activity as well as MMP-9 expression in TNF-alpha induced HASMC. Journal of Cellular Biochemistry 105: 524–533.PubMedCrossRef Suh, S.J., K.J. Cho, T.C. Moon, H.W. Chang, Y.G. Park, and C.H. Kim. 2008. 3,4,5-Trihydroxybenzaldehyde from Geum japonicum has dual inhibitory effect on matrix metalloproteinase 9; inhibition of gelatinoytic activity as well as MMP-9 expression in TNF-alpha induced HASMC. Journal of Cellular Biochemistry 105: 524–533.PubMedCrossRef
32.
Zurück zum Zitat Romanelli, R.G., I. Petrai, G. Robino, E. Efsen, E. Novo, A. Bonacchi, G. Pagliai, A. Grossi, M. Parola, N. Navari, W. Delogu, F. Vizzutti, K. Rombouts, P. Gentilini, G. Laffi, and F. Marra. 2006. Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 290: G120–G128.PubMedCrossRef Romanelli, R.G., I. Petrai, G. Robino, E. Efsen, E. Novo, A. Bonacchi, G. Pagliai, A. Grossi, M. Parola, N. Navari, W. Delogu, F. Vizzutti, K. Rombouts, P. Gentilini, G. Laffi, and F. Marra. 2006. Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 290: G120–G128.PubMedCrossRef
33.
Zurück zum Zitat Huang, C.Y., Y.C. Fong, C.Y. Lee, M.Y. Chen, H.C. Tsai, H.C. Hsu, and C.H. Tang. 2009. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochemical Pharmacology 77: 794–803.PubMedCrossRef Huang, C.Y., Y.C. Fong, C.Y. Lee, M.Y. Chen, H.C. Tsai, H.C. Hsu, and C.H. Tang. 2009. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochemical Pharmacology 77: 794–803.PubMedCrossRef
34.
Zurück zum Zitat Collins, T., and M.I. Cybulsky. 2001. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? The Journal of Clinical Investigation 107: 255–264.PubMedCrossRef Collins, T., and M.I. Cybulsky. 2001. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? The Journal of Clinical Investigation 107: 255–264.PubMedCrossRef
35.
Zurück zum Zitat Wang, Z., M.R. Castresana, and W.H. Newman. 2001. NF-kappaB is required for TNF-alpha-directed smooth muscle cell migration. FEBS Letters 508: 360–364.PubMedCrossRef Wang, Z., M.R. Castresana, and W.H. Newman. 2001. NF-kappaB is required for TNF-alpha-directed smooth muscle cell migration. FEBS Letters 508: 360–364.PubMedCrossRef
Metadaten
Titel
Triple Inhibitory Activity of Cliona celata Against TNF-α-Induced Matrix Metalloproteinase-9 Production Via Downregulated NF-κB and AP-1, Enzyme Activity, and Migration Potential
verfasst von
Seok-Jong Suh
Choong-Hwan Kwak
Kwon-Ho Song
Kyung-Min Kwon
Tae-Wook Chung
Seung-Hak Cho
Yeon-Kye Kim
Ho-Dong Yoon
Young-Choon Lee
Dong-Soo Kim
Sung-Jae Park
Min Kyun Na
Jong-Keun Son
Hyeun Wook Chang
Cheorl-Ho Kim
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9369-6

Weitere Artikel der Ausgabe 2/2012

Inflammation 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.